摘要
背景:FOXP2是forkhead box P(FOXP)家族的成员,据报道在乳腺癌中很重要。然而,其确切的机制和途径仍不清楚。目的:探讨FOXP2对三阴性乳腺癌(TNBC)肿瘤增殖和转移的影响及其分子机制。 方法:我们首先使用qRT-PCR检测TNBC细胞系和组织中的FOXP2表达。然后我们进行细胞增殖测定,集落形成测定和transwell测定以分析FOXP2在TNBC细胞中的表达的作用。进行小鼠异种移植模型以进一步证实FOXP2在TNBC中的作用。此外,我们使用qRT-PCR和Western印迹来获得FOXP2对GRP78表达的作用和qRT-PCR以分析GRP78在TNBC组织中的表达。我们进行了IHC分析以检测移植肿瘤中的FOXP2和GRP78表达,并使用相关分析进一步分析它们之间的关联。 结果:发现FOXP2在TNBC细胞系和组织中高度表达。 FOXP2敲低减弱了体外TNBC的生长和侵袭以及体内肿瘤进展和转移。此外,FOXP2敲减在TNBC细胞和移植肿瘤中下调葡萄糖调节的分子量为78的蛋白质(GRP78)表达。相关分析显示,GRP78的表达与TNBC细胞中FOXP2的表达呈正相关。 结论:FOXP2在TNBC中起关键作用,部分是通过调节GRP78,并可作为TNBC治疗的潜在靶点.
关键词: FOXP2,三阴性乳腺癌,增殖,转移,肿瘤.FOXP2,三阴性乳腺癌,增殖,转移,肿瘤。
图形摘要
Current Cancer Drug Targets
Title:FOXP2 Promotes Tumor Proliferation and Metastasis by Targeting GRP78 in Triple-negative Breast Cancer
Volume: 18 Issue: 4
关键词: FOXP2,三阴性乳腺癌,增殖,转移,肿瘤.FOXP2,三阴性乳腺癌,增殖,转移,肿瘤。
摘要: Background: FOXP2, a member of the forkhead box P (FOXP) family, has been reported to be important in breast cancer. However, its exact mechanisms and pathways remain unclear.
Objective: To investigate the effect of FOXP2 on tumor proliferation and metastasis in triplenegative breast cancer (TNBC) and study its underlying molecular mechanism.
Methods: We first used qRT-PCR to detect FOXP2 expression in TNBC cell lines and tissues. Then we conducted cell proliferation assays, colony formation assays, and transwell assays to analyze the effects of FOXP2 expression in TNBC cells. Mouse xenograft model was performed to further confirm the role of FOXP2 in TNBC. Moreover, we used qRT-PCR and Western blot to access the effect of FOXP2 on GRP78 expression and qRT-PCR to analyze GRP78 expression in TNBC tissues. We conducted IHC analysis to detect both FOXP2 and GRP78 expressions in transplanted tumors and used the correlation analysis to further analyze the link between them.
Results: FOXP2 was found to be highly expressed in TNBC cell lines and tissues. FOXP2 knockdown attenuated the growth and invasiveness of TNBC in vitro as well as tumor progression and metastasis in vivo. Moreover, FOXP2 knockdown downregulated glucose-regulated protein of molecular mass 78 (GRP78) expression in TNBC cells and transplanted tumors. Correlation analysis showed that GRP78 expression was positively associated with FOXP2 expression in TNBC cells.
Conclusion: FOXP2 plays a crucial role in TNBC, partly through modulating GRP78, and could act as a potential target for TNBC treatment.
Export Options
About this article
Cite this article as:
FOXP2 Promotes Tumor Proliferation and Metastasis by Targeting GRP78 in Triple-negative Breast Cancer, Current Cancer Drug Targets 2018; 18 (4) . https://dx.doi.org/10.2174/1568009618666180131115356
DOI https://dx.doi.org/10.2174/1568009618666180131115356 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Biogenic Silver and Zero-Valent Iron Nanoparticles by Feijoa: Biosynthesis, Characterization, Cytotoxic, Antibacterial and Antioxidant Activities
Anti-Cancer Agents in Medicinal Chemistry Influence of Gender on C-Reactive Protein, Fibrinogen, and Erythrocyte Sedimentation Rate in Obstructive Sleep Apnea
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Bacterial Translocation, Microcirculation Injury and Sepsis
Endocrine, Metabolic & Immune Disorders - Drug Targets Targeting ADAM17 Sheddase Activity in Cancer
Current Drug Targets Design of multifunctional nanocarriers for delivery of anti-cancer therapy
Current Pharmaceutical Design Trabectedin as a New Chemotherapy Option in the Treatment of Relapsed Platinum Sensitive Ovarian Cancer
Current Pharmaceutical Design An Advanced Computational Evaluation for the Most Biologically Active Enantiomers of Chiral Anti-Cancer Agents
Anti-Cancer Agents in Medicinal Chemistry Drug release from ordered mesoporous silicas
Current Pharmaceutical Design Bisacylimidoselenocarbamates Cause G2/M Arrest Associated with the Modulation of CDK1 and Chk2 in Human Breast Cancer MCF-7 Cells
Current Medicinal Chemistry Emerging Hsp90 Inhibitors: From Discovery to Clinic
Anti-Cancer Agents in Medicinal Chemistry Role of General Adversarial Networks in Mammogram Analysis: A Review
Current Medical Imaging Hypoxia Signaling and the Metastatic Phenotype
Current Molecular Medicine Role of ABC Transporters in Veterinary Drug Research and Parasite Resistance
Current Drug Delivery An Overview of Nano Delivery Systems for Targeting RNA Interference-based Therapy in Ulcerative Colitis
Current Pharmaceutical Design Molecular Imaging of Neuropsychiatry and Boron Neutron Capture Therapy in Neuro-oncology
Current Molecular Imaging (Discontinued) Brain Cancer: Implication to Disease, Therapeutic Strategies and Tumor Targeted Drug Delivery Approaches
Recent Patents on Anti-Cancer Drug Discovery Theoretical Modelling of Potential Chk1 Inhibitors
Letters in Drug Design & Discovery Targeting IL-17 and IL-23 in Immune Mediated Renal Disease
Current Medicinal Chemistry Peptide Activators of the p53 Tumor Suppressor
Current Pharmaceutical Design Synthesis of Arylamino-1,3,5-triazines Functionalized with Alkylatin 2-chloroethylamine Fragments and Studies of their Cytotoxicity on the Breast Cancer MCF-7 Cell Line
Anti-Cancer Agents in Medicinal Chemistry